Editas Medicine (NASDAQ:EDIT) Price Target Lowered to $5.00 at Barclays
Editas Medicine (NASDAQ:EDIT – Get Free Report) had its target price reduced by investment analysts at Barclays from $7.00 to $5.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Barclays‘s price objective indicates a potential upside of 52.44% from […]
More Stories
Palo Alto Networks (NASDAQ:PANW) Trading Up 0.6% – Still a Buy?
Shares of Palo Alto Networks, Inc. (NASDAQ:PANW – Get Free Report) rose 0.6% during mid-day trading on Tuesday . The...
Novo Nordisk A/S (NYSE:NVO) Stock Price Down 0.4% – Here’s What Happened
Novo Nordisk A/S (NYSE:NVO – Get Free Report)’s share price dropped 0.4% during trading on Tuesday . The stock traded...
Jackson Financial (NYSE:JXN) Announces Quarterly Earnings Results
Jackson Financial (NYSE:JXN – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $4.60 earnings per...
Ameresco (NYSE:AMRC) Updates FY 2024 Earnings Guidance
Ameresco (NYSE:AMRC – Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company...
SOPHiA GENETICS (NASDAQ:SOPH) Issues Earnings Results, Misses Expectations By $0.04 EPS
SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) released its quarterly earnings data on Tuesday. The company reported ($0.28) EPS for...
PHX Minerals Inc. (NYSE:PHX) Plans Quarterly Dividend of $0.04
PHX Minerals Inc. (NYSE:PHX – Get Free Report) declared a quarterly dividend on Wednesday, November 6th,Wall Street Journal reports. Stockholders...